دورية أكاديمية
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives
| العنوان: | Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives |
|---|---|
| المؤلفون: | Robert Jenke, Nina Reßing, Finn K. Hansen, Achim Aigner, Thomas Büch |
| المصدر: | Cancers, Vol 13, Iss 4, p 634 (2021) |
| بيانات النشر: | MDPI AG, 2021. |
| سنة النشر: | 2021 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | histone deacetylase, histone deacetylase inhibitor, cancer, bifunctional inhibitors, PROTAC, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | The increasing knowledge of molecular drivers of tumorigenesis has fueled targeted cancer therapies based on specific inhibitors. Beyond “classic” oncogene inhibitors, epigenetic therapy is an emerging field. Epigenetic alterations can occur at any time during cancer progression, altering the structure of the chromatin, the accessibility for transcription factors and thus the transcription of genes. They rely on post-translational histone modifications, particularly the acetylation of histone lysine residues, and are determined by the inverse action of histone acetyltransferases (HATs) and histone deacetylases (HDACs). Importantly, HDACs are often aberrantly overexpressed, predominantly leading to the transcriptional repression of tumor suppressor genes. Thus, histone deacetylase inhibitors (HDACis) are powerful drugs, with some already approved for certain hematological cancers. Albeit HDACis show activity in solid tumors as well, further refinement and the development of novel drugs are needed. This review describes the capability of HDACis to influence various pathways and, based on this knowledge, gives a comprehensive overview of various preclinical and clinical studies on solid tumors. A particular focus is placed on strategies for achieving higher efficacy by combination therapies, including phosphoinositide 3-kinase (PI3K)-EGFR inhibitors and hormone- or immunotherapy. This also includes new bifunctional inhibitors as well as novel approaches for HDAC degradation via PROteolysis-TArgeting Chimeras (PROTACs). |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 13040634 2072-6694 |
| العلاقة: | https://www.mdpi.com/2072-6694/13/4/634Test; https://doaj.org/toc/2072-6694Test |
| DOI: | 10.3390/cancers13040634 |
| الوصول الحر: | https://doaj.org/article/9134927d23934ce19cbc07415b577795Test |
| رقم الانضمام: | edsdoj.9134927d23934ce19cbc07415b577795 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 13040634 20726694 |
|---|---|
| DOI: | 10.3390/cancers13040634 |